Latest news and press releases about Intellia Therapeutics, Inc. (NTLA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema.
Price
| Price | $11.49 |
| Market Cap | $1.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.11 |
| EV / EBITDA | -4.29 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -57.79% |
| Return on Invested Capital | -52.86% |
| Return on Assets | -46.66% |
| Gross Margin | -46.48% |
| Operating Margin | -711.66% |
| Net Margin | -672.16% |
Related companies: BCRX · BHVN · IMNM · PHVS · STOK · SYRE · UPB
Explore sector: Healthcare · Biotechnology
More sections of NTLA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks